Patents by Inventor Charles J. Eyermann

Charles J. Eyermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240150375
    Abstract: Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: November 10, 2023
    Publication date: May 9, 2024
    Applicant: Theseus Pharmaceuticals, Inc.
    Inventors: Wei-Sheng HUANG, William C. SHAKESPEARE, Charles J. EYERMANN, David C. DALGARNO
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20230148005
    Abstract: Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: February 18, 2021
    Publication date: May 11, 2023
    Inventors: Wei-Sheng Huang, William C. SHAKESPEARE, Charles J. EYERMANN, David C. DALGARNO
  • Crystal Structure of Ump Kinase and Uses Thereof
    Publication number: 20090209022
    Abstract: The present invention relates crystals of UMP kinase and computer-assisted methods for screening, identifying, and designing inhibitors and allosteric modulators of UMP kinase.
    Type: Application
    Filed: August 15, 2005
    Publication date: August 20, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Jason Breed, Peter Doig, Charles J. Eyermann, Richard Pauptit, Julie Tucker
  • Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
    Patent number: 5610294
    Abstract: This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral infection. A representative compound of the invention is the compound of formula: ##STR1## wherein R.sup.22 and R.sup.23 are allyl.
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: March 11, 1997
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Patrick Y. Lam, Prabhakar K. Jadhav, Charles J. Eyermann, Carl N. Hodge, George V. De Lucca, James D. Rodgers
  • Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
    Patent number: 5523302
    Abstract: This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: June 4, 1996
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Charles J. Eyermann
  • Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
    Patent number: RE37781
    Abstract: This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral infection. A representative compound of the invention is the compound of formula: wherein R22 and R23 are allyl.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: July 2, 2002
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Patrick Y. Lam, Prabhakar K. Jadhav, Charles J. Eyermann, Carl N. Hodge, George V. De Lucca, James D. Rodgers